Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hospira, a provider of generic injectable pharmaceuticals, has obtained FDA approval for Meropenem for injection, USP (IV) 500mg and 1g vials. The medication, a carbapenem that belongs to the beta-lactam class of antibiotics, is a generic version of AstraZeneca's Merrem IV.
Subscribe to our email newsletter
Beta-lactam antibiotics represent a class of drugs with a wide spectrum of antibacterial activity. Hospira said that Meropenem represents the first US drug launch from its recent acquisition of the generic injectables business of Orchid Chemicals & Pharmaceuticals.
Thomas Moore, president of Hospira for US region, said: “This is the first generic carbapenem approved in the US. Hospira is committed to continuing to reduce the cost of healthcare spending by providing savings with first-to-market generic launches.”
Hospira’s specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. Hospira offers portfolio of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions.